When looking closer, we found that tumor DP-3 was considered HER2 negative with an IHC score of 1+ from examined core needle biopsy before the patient received neoadjuvant therapy as for a luminal B HER2-negative tumor. This evidence concerns the gene ERBB2 and neoplasm.